Evaxion, Penn State publish preclinical data validating AI-based viral vaccine discovery platform

 Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in Frontiers of Immunology of preclinical data demonstrating the effectiveness of its proprietary AI-driven viral vaccine discovery platform. The presented preclinical study was conducted in collaboration with associate professor Girish Kirimanjeswara, Pennsylvania State University, US.

The published data showcase how Evaxion's proprietary AI-platform, RAVEN (Rapidly Adaptive Viral Response), identifies broad and robust T-cell epitopes from SARS-CoV-2 that protect against mortality and severe disease in a COVID-19 mouse model. This research demonstrates the potential of the RAVEN platform to accelerate the development of effective viral vaccines, leveraging the power of artificial intelligence.

https://www.biospace.com/article/releases/evaxion-and-pennsylvania-state-university-publish-preclinical-data-validating-our-ai-based-viral-vaccine-discovery-platform/